Lv4
780 积分 2026-02-23 加入
Cellular neighborhoods in cancer
1天前
已完结
Retlirafusp Alfa: First Approval
9天前
已完结
Antibodies to watch in 2026
9天前
已完结
Enlonstobart: First Approval
9天前
已完结
Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer
9天前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
10天前
已完结
Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
10天前
已完结
Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions
24天前
已完结
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
1个月前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
